RxDoctor Payments Data

Michael Bober

Clinical Genetics (M.D.) · Wilmington, DENPI 1255422531

Payments from drug & device makers

$1,983,574in general payments, 2019–2025

Across 614 payments — averaging $3230.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biomarin Pharmaceutical Inc.$1.3M
  • Pfizer$218K
  • QED Therapeutics, Inc.$204K
  • Swedish Orphan Biovitrum AB$114K
  • Ultragenyx Pharmaceutical Inc.$57K
  • Shire North American Group Inc$37K
  • plus $63K from 5 others

What the payments were for

  • Consulting fees$25,08134%
  • Speaking & faculty fees$30,35542%
  • Travel & lodging$12,40817%
  • Food & beverage$1,1952%
  • Education$4,0386%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical genetics (m.d.) providers in Delawareto place this figure against a meaningful peer group, so we don't.

Other clinical genetics (m.d.) in Wilmington

Where these figures come from

Is this you, or does something look wrong? →